- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02628795
Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement (TWEAK)
July 3, 2021 updated by: Marcas M. Bamman, PhD, University of Alabama at Birmingham
This single-blind, randomized, controlled trial is designed to test the effect of an intensive, 16 week exercise rehabilitation program (progressive resistance training + functional mobility training) vs. usual care on restoration of muscle mass and mobility after total hip (THA) or knee (TKA) arthroplasty in men and women with end-stage osteoarthritis.
The molecular basis underlying the trial is the presence of significant muscle inflammation susceptibility in many of these individuals, and the expectation that the more intensive intervention will overcome this inflammatory burden to facilitate recovery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
While elective total hip (THA) and knee (TKA) arthroplasty relieve pain and improve mobility function for thousands with end-stage osteoarthritis (OA), up to 35% endure persistent muscle atrophy and mobility limitations for several years that impact life quality, increase morbidity, and burden the healthcare system.
Given that THA/TKA volumes are increasing exponentially with >1.1 million in the US annually, refractory mobility impairment is a major public health problem.
Together, the available data raise two important knowledge gaps in THA/TKA rehabilitation: (i) poorly understood factors that limit responsiveness of a large number of patients to current usual care; and (ii) the absence of rehabilitation programs proven to overcome these limitations.
The proposed project is designed to fill these gaps.
The investigators' fundamental tenet is that restoration of mobility function following THA/TKA requires: (i) regeneration of surgically damaged muscle; and (ii) regrowth of muscles that have atrophied over years of OA and limited usage.
The investigators suggest a major cause of muscle regeneration impairment in some individuals is what the investigators identified as muscle inflammation susceptibility (MuIS) - hyperactive inflammatory signaling in muscle of MuIS(+) individuals despite no systemic inflammation - which also manifests in isolated primary satellite cells and inhibits myogenesis in vitro, indicative of a true cellular phenotype beyond the niche.
The investigators' preliminary findings in THA/TKA patients strongly suggest the tumor necrosis factor-like weak inducer of apoptosis (TWEAK) signaling pathway may be central to MuIS and impaired THA/TKA recovery, as high perioperative muscle TWEAK signaling in the ipsilateral thigh was the most sensitive indicator of impaired muscle protein synthesis and failed strength recovery after 8 wk of usual care.
Progressive resistance exercise training (PRT) is a putative anabolic intervention that the investigators find consistently increases muscle mass to meet healthy standards in atrophied and mobility-impaired adults, by activating muscle protein synthesis and the myogenic activity of muscle satellite cells.
Together, these findings raise the central hypothesis that PRT plus adjunctive functional mobility training (PRT+FM) after THA/TKA will more effectively restore muscle mass and mobility function to healthy standards than usual care and, because MuIS(+) are predicted to suffer failed muscle recovery and persistent dismobility under usual care, the impact of PRT+FM will be greatest in MuIS(+).
The investigators will thoroughly test this hypothesis in a randomized controlled trial of 88 THA/TKA patients with the following aims.
Aim 1: To determine the effects of 16 wk of PRT+FM vs. usual care after elective THA/TKA on muscle mass, performance, and mobility function.
Aim 2: To determine whether MuIS status modifies the effects of PRT+FM or usual care after THA/TKA.
Cellular and molecular mechanisms of muscle mass regulation will be studied in detail.
Aim 3. To determine the long-term impact of 16 wk PRT+FM by re-assessing outcomes at 6 mo and 1 y.
The investigators fully expect the novel findings to lead a paradigm shift in THA/TKA rehabilitation that will have a profound impact on a growing segment of the population.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- UAB Center for Exercise Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Between the ages 40 and 80 y.
- Scheduled to undergo elective total hip or knee replacement specifically for the surgical indication of end-stage osteoarthritis.
- First-time hip or knee replacement.
- Capable of providing informed consent (cognitively intact if consenting to surgery).
Exclusion Criteria:
Any surgical indication other than first-time total joint replacement specifically for end-stage osteoarthritis.
- Bilateral knee/ hip replacement
- History of alcoholism or liver disease.
- Any history of hypo- or hyper-coagulation disorders including subjects taking Coumadin.
- Any individual with end-stage disease and/or a life expectancy less than one year.
- Pregnancy.
- Lactating Women.
- Neurological, musculoskeletal, or other disorder that would preclude them from completing the exercise training intervention and all performance tests.
- Uncontrolled hypertension, unstable or exercise-induced angina pectoris or myocardial ischemia, congestive heart failure.
- Uncontrolled diabetes mellitus.
- Any other condition or events considered exclusionary by the PIs and/or physician Co-Is.
- Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle biopsy procedure).
- Phenylketonuria (phenylalanine tracer for metabolic studies).
- Currently receiving androgen (e.g., testosterone) or anabolic (e.g., growth hormone (GH), insulin-like growth factor-I (IGF-I)) therapy.
- Body mass index ≥ 35.
- History of lower body progressive resistance training within the past year.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PRT + FM
Progressive resistance training + functional mobility training 3 d/wk x 16 wk
|
Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
Post-surgical usual care activities including any prescribed physical therapy
|
|
Active Comparator: Usual Care
Post-surgical usual care including physical therapy
|
Post-surgical usual care activities including any prescribed physical therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in unilateral (surgical) thigh muscle mass (unit of measure = grams)
Time Frame: Pre-surgery to 16 weeks post-surgery
|
Primary muscle mass outcome of Aim 1
|
Pre-surgery to 16 weeks post-surgery
|
|
Change in unilateral (surgical) knee extension power (unit of measure = watts)
Time Frame: Pre-surgery to 16 weeks post-surgery
|
Primary functional outcome of Aim 1
|
Pre-surgery to 16 weeks post-surgery
|
|
Change in short physical performance battery (SPPB) (unit of measure = score)
Time Frame: From 16 weeks post-surgery to 26 and 52 weeks post-surgery
|
Primary outcome of Aim 3
|
From 16 weeks post-surgery to 26 and 52 weeks post-surgery
|
|
Muscle inflammation susceptibility (MuIS) status (unit of measure = relative value)
Time Frame: At the time of surgery
|
Primary outcome of Aim 2: Muscle inflammation susceptibility (MuIS) defined by TWEAK receptor gene expression
|
At the time of surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in muscle fiber size (unit of measure = micrometers squared)
Time Frame: From the time of surgery to 16 weeks post-surgery
|
From the time of surgery to 16 weeks post-surgery
|
|
Change in unilateral (surgical) knee extension isometric strength (unit of measure = Newton-meters)
Time Frame: Pre-surgery to 16 weeks post-surgery
|
Pre-surgery to 16 weeks post-surgery
|
|
Change in maximum 10-meter gait speed (unit of measure = meters per second)
Time Frame: Pre-surgery to 16 weeks post-surgery
|
Pre-surgery to 16 weeks post-surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in free-living physical activity (unit of measure = steps per day)
Time Frame: Pre-surgery to 8, 16, 26, and 52 weeks post-surgery
|
Via wearable technology (i.e.
step counter)
|
Pre-surgery to 8, 16, 26, and 52 weeks post-surgery
|
|
Change in self-reported health status (unit of measure = score)
Time Frame: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Via Short Form-36v2 Health Survey (SF-36v2)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
|
Change in cellular and molecular markers (unit of measure = arbitrary units)
Time Frame: From the time of surgery to 16 weeks post-surgery
|
Experiments using muscle tissue and primary muscle satellite cells collected from surgical and contralateral limbs.
|
From the time of surgery to 16 weeks post-surgery
|
|
Change in fatigue (unit of measure = score)
Time Frame: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Via Patient Reported Outcomes Measurement Information System (PROMIS)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
|
Change in pain (unit of measure = score)
Time Frame: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Via Patient Reported Outcomes Measurement Information System (PROMIS)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
|
Change in depression (unit of measure = score)
Time Frame: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Beck Depression Inventory (BDI II)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
|
Change in fatigue severity (unit of measure = score)
Time Frame: Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Fatigue Severity Scale (FSS)
|
Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Marcas M Bamman, PhD, University of Alabama at Birmingham
- Principal Investigator: S Louis Bridges, MD, PhD, University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2015
Primary Completion (Actual)
September 1, 2020
Study Completion (Actual)
February 28, 2021
Study Registration Dates
First Submitted
August 5, 2015
First Submitted That Met QC Criteria
December 10, 2015
First Posted (Estimate)
December 11, 2015
Study Record Updates
Last Update Posted (Actual)
July 7, 2021
Last Update Submitted That Met QC Criteria
July 3, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01HD084124 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Data might be provided on written request in aggregate form.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Hacettepe UniversityNot yet recruitingThumb Osteoarthritis | Trapeziometacarpal Osteoarthritis | Carpometacarpal Osteoarthritis | Thumb Basal Joint OsteoarthritisTurkey (Türkiye)
-
Sanford HealthTerminatedKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
Edin MešanovićCompletedOsteoarthritis | Osteoarthritis of the Knee | Osteoarthritis of Knee | Osteoarthritis of the Knees | Osteoarthritis (OA) of the Knee | Osteoarthritis Knee | Osteoarthritis in the Knee | Osteoarthritis of Knee JointBosnia and Herzegovina
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Golden Jubilee National HospitalJohnson & Johnson; DePuy OrthopaedicsNot yet recruitingOsteoarthritis | Knee Osteoarthritis | Osteoarthritis (OA) | Osteo Arthritis | Osteoarthritis in the Knee | Osteoarthritis (Knee) | Osteo Arthritis of the KneeUnited Kingdom
-
Middlesex UniversityRecruitingOsteoarthritis | Osteoarthritis (OA) | Osteoarthritis (OA) of the Knee | Osteoarthritis (OA) of the HipUnited Kingdom
-
University of EdinburghHospital for Special Surgery, New YorkActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Istanbul University - CerrahpasaCompletedKnee Osteoarthritis | Knee Osteoarthritis (Knee OA)Turkey (Türkiye)
Clinical Trials on PRT + FM
-
Oulu University HospitalLoisto Terveys, Oulu; Fysios Kastelli, Oulu; Faskia-Markus, OuluEnrolling by invitationLow Back Pain | Low Back Pain, RecurrentFinland
-
Shanghai General Hospital, Shanghai Jiao Tong University...CompletedInherited Retinal DiseasesChina
-
C.B. Fleet Company, Inc.CompletedBowel Cleansing Prior to ColonoscopyUnited States
-
Indiana UniversityRichard L. Roudebush VA Medical CenterCompleted
-
University of the Basque Country (UPV/EHU)CompletedIntellectual Disability
-
University of AarhusAarhus University Hospital; Vejle Hospital; Gødstrup Hospital; Regionshospitalet... and other collaboratorsRecruiting
-
Proteon TherapeuticsUniversity of California, San FranciscoCompletedPeripheral Artery DiseaseUnited States
-
Proteon TherapeuticsCompletedChronic Kidney DiseaseUnited States
-
Stanford UniversityCompletedAutistic Disorder | Developmental DisabilitiesUnited States
-
Stanford UniversityAnonymous DonorRecruitingAutism Spectrum Disorder | Autism | ASDUnited States